News &amp; Updates

Among patients with treatment-naïve autoimmune hepatitis, more of those who receive mycophenolate mofetil achieve remission than those who receive azathioprine, as shown in the results of the CAMARO trial.

Mycophenolate mofetil prompts remission better than azathioprine in autoimmune hepatitis

Rotavirus infection linked to gastroenteritis, neurological complications in children

Children with rotavirus infection are at risk of developing gastroenteritis with severe but self-limiting neurological manifestations, reveals a study.

Rotavirus infection linked to gastroenteritis, neurological complications in children

20 Jul 2023

Simvastatin plus beta blocker improves survival of cirrhotic patients with variceal bleeding

The addition of simvastatin to a nonselective beta blocker results in better survival among cirrhotic patients with variceal bleeding, reports a study presented at EASL 2023.

Simvastatin plus beta blocker improves survival of cirrhotic patients with variceal bleeding

Ketogenic diet reduces weight, raises aldosterone

Adherence to ketogenic diets (KDs) results in weight reduction and increased aldosterone concentrations without worsening cardiometabolic risk factors, suggests a study.

Ketogenic diet reduces weight, raises aldosterone

Adverse neurodevelopmental outcomes higher in complicated twins

Survivors of complicated monochorionic diamniotic (MCDA) twin pregnancies (ie, complicated twins) have a higher rate of adverse neurodevelopmental outcomes compared with uncomplicated twins, suggests a study presented at RCOG 2023.

Adverse neurodevelopmental outcomes higher in complicated twins

Oral health screening holds potential for diabetes prevention

Basic indicators of oral health appear to be associated with the risk of developing diabetes, according to a study, suggesting the importance of oral health screening for preventing diabetes.

Oral health screening holds potential for diabetes prevention

Tirzepatide induces weight loss in overweight/obese patients with T2D

Treatment with once-weekly tirzepatide, a GIP* and GLP-1** receptor agonist, led to a substantial weight reduction among overweight or obese adults with type 2 diabetes (T2D), according to the phase III SURMOUNT-2 trial presented at ADA 2023.

Tirzepatide induces weight loss in overweight/obese patients with T2D

Tirzepatide bests placebo, other glucose-lowering drugs at keeping lipid levels, waistline in check

Treatment with tirzepatide is associated with better lipid profile and waist circumference outcomes compared with placebo and other glucose-lowering drugs, according to a study.

Tirzepatide bests placebo, other glucose-lowering drugs at keeping lipid levels, waistline in check

Resmetirom delivers improved outcomes for NASH patients with fibrosis

19 Jul 2023 by

The THR-β selective agonist resmetirom helps resolve nonalcoholic steatohepatitis (NASH) and reduce fibrosis, with the drug being safe and well-tolerated, according to data from the large phase III pivotal MAESTRO-NASH trial presented at EASL 2023.

Resmetirom delivers improved outcomes for NASH patients with fibrosis

Baseline HbA1c strongly predicts metformin failure

Baseline glycated haemoglobin (HbA1c) is the most robust risk factor for metformin failure, reveals a study, noting that routinely available clinical data may be used to identify high-risk patients who may benefit from closer monitoring and earlier treatment intensification.

Baseline HbA1c strongly predicts metformin failure